Jennifer Dumoulin - Concepedia

Author

Jennifer Dumoulin

Université Paris-Saclay

Also Known As

J Dumoulin, J. DUMOULIN, J. Dumoulin, Jean-François Dumoulin, Jennifer DUMOULIN, Jennifer Dumoulin

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Université Paris-Saclay Hôpital Ambroise-Paré Université de Versailles Saint-Quentin-en-Yvelines Assistance Publique – Hôpitaux de Paris Hôpital Raymond-Poincaré

About

Jennifer Dumoulin is an author at Université Paris-Saclay specializing in medicine, lung cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	4	560
2	Pathology	2	2	254
3	Critical Care Medicine	1	2	306
4	Immunology	1	1	172
5	Pulmonary Medicine	1	2	306

Jennifer Dumoulin

Publications

875

Citations

H-Index

Page 1

	Year	Citations
Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort Lorenzo Guglielmetti, D. Le Dû, M. Jachym, Clinical Infectious Diseases	2014	182
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab Adrien Costantini, Catherine Julié, Coraline Duménil, OncoImmunology ImmunologyImmunoeditingPathologyImmunotherapeuticsLow Sgranb	2018	172
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial Aurélien Dinh, Jacques Ropers, Clara Duran, The Lancet Community-acquired PneumoniaCritical Care MedicineAntibioticsAntimicrobial StewardshipAcute Care	2021	153
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Duménil, Journal for ImmunoTherapy of Cancer	2019	96
Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer Etienne Giroux‐Leprieur, Guillaume Herbretau, Coraline Duménil, OncoImmunology Tumor ResponseProlonged Clinical BenefitAdvanced NsclcCancer DetectionMedicine	2018	82
Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab Coraline Duménil, Marie-Ange Massiani, Jennifer Dumoulin, PLoS ONE	2018	58
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression Etienne Giroux‐Leprieur, Zofia Hélias‐Rodzewicz, Paul Takam Kamga, Journal for ImmunoTherapy of Cancer	2020	33
Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Camille Mehlman, Paul Takam Kamga, Adrien Costantini, Cancers	2021	23
Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events Marwa Bachir, Lorenzo Guglielmetti, Simone Tunesi, International Journal of Infectious Diseases	2021	20
Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia Aurélien Dinh, Clara Duran, Jacques Ropers, JAMA Network Open	2021	19

Page 1